Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
LLY

LLY - Eli Lilly & Co Stock Price, Fair Value and News

859.25USD+10.35 (+1.22%)Delayed as of 19 Jul 2024, 01:58 pm ET

Market Summary

LLY
USD859.25+10.35
Delayedas of 19 Jul 2024, 01:58 pm
1.22%

LLY Alerts

  • 1 major insider sales recently.

LLY Stock Price

View Fullscreen

LLY RSI Chart

LLY Valuation

Market Cap

807.0B

Price/Earnings (Trailing)

131.46

Price/Sales (Trailing)

22.46

EV/EBITDA

90.84

Price/Free Cashflow

219.56

LLY Price/Sales (Trailing)

LLY Profitability

EBT Margin

21.04%

Return on Equity

47.91%

Return on Assets

9.6%

Free Cashflow Yield

0.46%

LLY Fundamentals

LLY Revenue

Revenue (TTM)

35.9B

Rev. Growth (Yr)

25.98%

Rev. Growth (Qtr)

-6.26%

LLY Earnings

Earnings (TTM)

6.1B

Earnings Growth (Yr)

66.77%

Earnings Growth (Qtr)

2.43%

Breaking Down LLY Revenue

52 Week Range

879.50
(Low)(High)

Last 7 days

-9.1%

Last 30 days

-4.7%

Last 90 days

16.9%

Trailing 12 Months

87.2%

How does LLY drawdown profile look like?

LLY Financial Health

Current Ratio

1.35

Debt/Equity

1.92

Debt/Cashflow

0.15

LLY Investor Care

Dividend Yield

0.75%

Dividend/Share (TTM)

6.8

Shares Dilution (1Y)

0.12%

Diluted EPS (TTM)

6.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202435.9B000
202327.7B29.5B32.1B34.1B
202229.3B29.1B29.2B28.5B
202125.5B26.7B27.8B28.3B
202023.1B22.9B23.2B24.5B
201921.6B21.7B21.8B22.3B
201820.4B20.9B21.3B21.5B
201720.9B20.6B20.3B20.0B
201620.2B20.6B20.8B21.2B
201519.6B19.6B19.7B20.0B
201422.2B21.2B20.3B19.6B
201322.6B22.9B23.3B23.1B
201224.0B23.4B22.7B22.6B
201123.4B23.9B24.4B24.3B
201022.3B22.7B22.8B23.1B
200920.6B20.8B21.1B21.8B
2008019.2B19.8B20.4B
200700018.6B

Tracking the Latest Insider Buys and Sells of Eli Lilly & Co

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 15, 2024
johnson kimberly h
acquired
9,504
950
10.00
-
Jul 15, 2024
luciano juan r
acquired
15,207
950
16.00
-
Jul 15, 2024
sulzberger gabrielle
acquired
9,504
950
10.00
-
Jul 15, 2024
alvarez ralph
acquired
11,405
950
12.00
-
Jul 15, 2024
hedley mary lynne
acquired
9,504
950
10.00
-
Jul 10, 2024
lilly endowment inc
sold
-197,361,000
939
-210,000
-
Jul 08, 2024
lilly endowment inc
sold
-85,978,000
918
-93,593
-
Jul 05, 2024
lilly endowment inc
sold
-47,927,200
915
-52,369
-
Jul 03, 2024
lilly endowment inc
sold
-8,098,650
915
-8,848
-
Jul 01, 2024
lilly endowment inc
sold
-53,770,800
915
-58,749
-

1–10 of 50

Which funds bought or sold LLY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Shulman DeMeo Asset Management LLC
reduced
-0.5
245,528
1,798,860
0.47%
Jul 17, 2024
Welch Group, LLC
added
6.7
1,117,340
5,739,200
0.28%
Jul 17, 2024
Relyea Zuckerberg Hanson LLC
added
6.75
466,450
2,391,840
0.40%
Jul 17, 2024
TL Private Wealth
unchanged
-
123,884
631,716
0.29%
Jul 17, 2024
ATTICUS WEALTH MANAGEMENT, LLC
reduced
-3.62
156,281
1,446,390
0.47%
Jul 17, 2024
COMMUNITY TRUST & INVESTMENT CO
unchanged
-
185,650
1,319,140
0.09%
Jul 17, 2024
WEDGE CAPITAL MANAGEMENT L L P/NC
reduced
-0.35
105,591
766,857
0.01%
Jul 17, 2024
HENGEHOLD CAPITAL MANAGEMENT LLC
added
13.42
115,050
474,594
0.05%
Jul 17, 2024
Montecito Bank & Trust
reduced
-1.2
1,175,610
9,022,110
1.83%
Jul 17, 2024
BROWN, LISLE/CUMMINGS, INC.
reduced
-1.21
240,998
1,850,600
0.60%

1–10 of 49

Are Funds Buying or Selling LLY?

Are funds buying LLY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LLY
No. of Funds

Unveiling Eli Lilly & Co's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
7.54%
71,604,696
SC 13G/A
Feb 09, 2024
pnc financial services group, inc.
5.43%
51,540,105
SC 13G/A
Jan 29, 2024
blackrock inc.
6.8%
64,376,027
SC 13G/A
Jan 26, 2024
lilly endowment inc
10.51%
99,768,810
SC 13G/A
Feb 10, 2023
pnc financial services group, inc.
5.25%
51,829,873
SC 13G/A
Feb 09, 2023
vanguard group inc
7.73%
73,429,863
SC 13G/A
Feb 01, 2023
blackrock inc.
6.9%
65,467,793
SC 13G/A
Jan 25, 2023
lilly endowment inc
10.83%
102,948,810
SC 13G/A
Feb 11, 2022
pnc financial services group, inc.
5.42%
51,888,455
SC 13G/A
Feb 09, 2022
vanguard group inc
7.24%
69,261,754
SC 13G/A

Recent SEC filings of Eli Lilly & Co

View All Filings
Date Filed Form Type Document
Jul 16, 2024
4
Insider Trading
Jul 16, 2024
4
Insider Trading
Jul 16, 2024
4
Insider Trading
Jul 16, 2024
4
Insider Trading
Jul 16, 2024
4
Insider Trading
Jul 11, 2024
4
Insider Trading
Jul 10, 2024
144
Notice of Insider Sale Intent
Jul 10, 2024
8-K
Current Report
Jul 09, 2024
4
Insider Trading
Jul 08, 2024
4
Insider Trading

Peers (Alternatives to Eli Lilly & Co)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
374.1B
85.6B
6.72% -2.08%
9.72
4.37
5.68% 202.39%
315.0B
61.4B
-2.82% 17.39%
136.61
5.13
6.11% -82.30%
177.5B
29.5B
8.12% 42.57%
47.16
6.01
12.76% -52.47%
168.3B
35.0B
8.35% -18.50%
144.83
4.8
-26.40% -92.03%
91.6B
27.4B
16.41% -6.90%
189.03
3.34
1.51% -91.32%
18.3B
16.0B
-3.94% 90.89%
-37.11
1.15
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.02% -22.25%
9.6
2.42
54.01% 364.56%
3.8B
4.6B
8.22% -19.25%
-489.51
0.83
-0.06% 94.55%
2.7B
9.0B
14.06% -20.56%
-5.95
0.3
10.01% -27.45%
1.9B
676.2M
-0.80% -36.26%
12.57
2.87
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
7.69% 2.82%
-4
1.9
24.65% 80.36%
20.9M
1.3M
-2.69% -55.31%
-2.82
16.12
-98.14% -104.71%
14.6M
89.6M
10.26% -18.10%
-1.03
0.19
287.27% -129.41%
9.9M
21.5M
323.53% -53.25%
-1.28
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Eli Lilly & Co News

Latest updates
Investopedia70 minutes ago
Simply Wall St16 Jul 202410:33 am

Eli Lilly & Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-6.3%8,7689,3539,4998,3126,9607,3026,9426,4887,8108,0006,7736,7406,8067,4405,7415,4995,8606,1145,4775,6375,092
  S&GA Expenses1.4%1,9521,9251,8041,9251,7491,6431,6141,6251,5581,5921,5781,6861,5761,5541,5691,4491,5501,6981,4121,5861,517
  R&D Expenses----2,3571,9851,9961,8031,7821,6101,8981,7051,6551,6721,7291,4651,3901,3921,5811,3811,4021,231
EBITDA Margin7.2%0.25*0.24*0.24*0.30*0.28*0.29*0.28*0.27*0.29*0.27*0.30*0.32*---------
Income Taxes-8.1%293319485326185159114138151114135204121352229232223167152139170
Earnings Before Taxes1.1%2,5362,5094272,0891,5302,0961,5661,0912,0541,8401,2451,5941,4762,4691,4371,6441,6801,6631,4061,466731
EBT Margin9.6%0.21*0.19*0.19*0.25*0.23*0.24*0.22*0.21*0.23*0.22*0.24*0.26*---------
Net Income2.4%2,2432,190-57.401,7631,3451,9381,4529531,9031,7261,1101,3901,3552,1171,2081,4121,4571,4961,2541,3274,242
Net Income Margin11.2%0.17*0.15*0.16*0.22*0.21*0.22*0.21*0.20*0.21*0.20*0.22*0.23*---------
Free Cashflow473.8%1,166-3112,1906321,7311,6632,2171,1832,5232,2621,6311,776---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.1%63,94464,00657,91654,81453,16349,49047,46247,06446,91948,80648,18747,80946,83846,63343,94641,96741,10339,28637,89338,66638,007
  Current Assets-2.1%25,18925,72723,00721,33220,81118,03517,64017,11516,96518,45217,80817,29616,60517,46216,24014,58213,99413,71012,66213,45512,598
    Cash Equivalents-12.7%2,4602,8192,3812,6953,5462,0672,6172,6232,4593,8193,7883,2203,0023,6573,5952,3651,6992,338-2,2902,036
  Inventory5.7%6,1025,7734,9014,7994,5454,3103,8313,8993,8933,8863,9073,8253,6613,9803,5553,3143,1023,1913,1013,1813,055
  Net PPE5.5%13,62412,91411,86311,27710,54610,1449,3119,1289,1038,9858,9208,8568,6308,6828,2817,9817,8987,8737,8027,8487,780
  Goodwill0.0%4,9404,9404,0854,0794,0734,0733,8923,8923,8923,8923,8843,8843,8773,7673,7263,7233,7793,6793,7733,8203,856
  Current Liabilities-31.9%18,59827,29321,99818,91516,01017,13815,65315,62113,38615,05313,68215,09311,71412,48211,97711,98912,61011,77510,82911,85511,236
  Long Term Debt34.1%24,56018,32117,92418,15818,88114,73814,14414,69215,15315,34615,52214,73716,20016,58716,33515,06413,98213,81813,66213,71813,610
    LT Debt, Non Current34.1%24,56018,32117,92418,15818,88114,73814,14414,69215,15315,34615,52214,73716,20016,58716,33515,06413,98213,81813,66213,71813,610
Shareholder's Equity18.9%12,81210,77211,22011,06414410,04391.008,5565945967.006,6696,89915.007,15415.006.004,9203,3836,5355,757
  Retained Earnings21.7%12,55410,31210,31010,36910,63910,04310,0078,5569,3698,9599,6398,5309,1817,8307,1546,6175,8794,9204,9824,3184,879
  Additional Paid-In Capital-3.3%7,0107,2507,1606,9496,7936,9216,8296,7466,6566,8336,7586,6696,5796,7796,6996,6296,5566,6856,6096,5355,757
Accumulated Depreciation1.2%11,23511,09910,76810,63210,48610,23310,07410,12010,1389,9779,9639,8429,6439,5719,6019,2979,1429,1629,0558,9568,792
Shares Outstanding0.1%901900900900901902901902904907907908---------
Minority Interest-7.2%85.0092.0087.0086.0010512696.0011513117619721920118416917911892.0080.0077.0085.00
Float----398,291---274,342---193,649---138,907---93,167-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations473.8%1,166-3112,1906321,7311,6632,2171,1832,5232,2621,6311,7761,6971,8151,8072,4953821,9641,5101,052311
  Share Based Compensation32.6%15912021616213193.0085.0092.0010175.0090.0092.0086.0088.0072.0077.0072.0082.0076.0080.0076.00
Cashflow From Investing59.7%-1,177-2,924-3,080-459-688-943-955-826-1,037-484-616-483-1,283-674-313-210-1,060-41.40-42361.00-7,678
Cashflow From Financing-108.8%-3113,545572-1,033412-1,141-1,263-123-2,878-1,526-463-1,083-1,058-1,291-279-1,673107-1,113-1,692-8851,368
  Dividend Payments14.8%1,1691,0181,0161,0181,017884882884886773770768775670672674671587587598637
  Buy Backs-----750---1,500750-500----500300600-3,500
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LLY Income Statement

2024-03-31
Consolidated Condensed Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue (Note 2)$ 8,768.0$ 6,960.0
Costs, expenses, and other:  
Cost of sales1,673.51,626.7
Research and development2,522.81,985.1
Marketing, selling, and administrative1,952.21,749.2
Acquired in-process research and development (Note 3)110.5105.0
Other–net, (income) expense (Note 11)(27.1)(35.7)
Costs, expenses, and other6,231.95,430.3
Income before income taxes2,536.11,529.7
Income taxes (Note 7)293.2184.8
Net income$ 2,242.9$ 1,344.9
Earnings per share:  
Basic (in dollars per share)$ 2.49$ 1.49
Diluted (in dollars per share)$ 2.48$ 1.49
Shares used in calculation of earnings per share:  
Basic (in shares)900.8901.0
Diluted (in shares)903.8903.3

LLY Balance Sheet

2024-03-31
Consolidated Condensed Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current Assets  
Cash and cash equivalents (Note 6)$ 2,460.2$ 2,818.6
Short-term investments (Note 6)126.1109.1
Accounts receivable, net of allowances of $14.3 (2024) and $14.8 (2023)7,885.69,090.5
Other receivables2,127.92,245.7
Inventories (Note 5)6,101.85,772.8
Prepaid expenses6,348.65,540.8
Other current assets138.6149.5
Total current assets25,188.825,727.0
Investments (Note 6)3,086.93,052.2
Goodwill4,939.64,939.7
Other intangibles, net6,762.26,906.6
Deferred tax assets5,633.95,477.3
Property and equipment, net of accumulated depreciation of $11,235.0 (2024) and $11,099.3 (2023)13,624.012,913.6
Other noncurrent assets4,708.14,989.9
Total assets63,943.564,006.3
Current Liabilities  
Short-term borrowings and current maturities of long-term debt1,651.56,904.5
Accounts payable2,473.72,598.8
Employee compensation844.21,650.4
Sales rebates and discounts9,429.611,689.0
Dividends payable0.01,169.2
Other current liabilities4,199.13,281.3
Total current liabilities18,598.127,293.2
Noncurrent Liabilities  
Long-term debt24,559.918,320.8
Accrued retirement benefits (Note 8)1,427.91,438.8
Long-term income taxes payable4,189.43,849.2
Other noncurrent liabilities2,270.82,240.6
Total noncurrent liabilities32,448.025,849.4
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity  
Common stock594.2593.6
Additional paid-in capital7,009.57,250.4
Retained earnings12,553.910,312.3
Employee benefit trust(3,013.2)(3,013.2)
Accumulated other comprehensive loss (Note 10)(4,299.5)(4,327.0)
Cost of common stock in treasury(32.7)(44.2)
Total Eli Lilly and Company shareholders' equity12,812.210,771.9
Noncontrolling interests85.291.8
Total equity12,897.410,863.7
Total liabilities and equity$ 63,943.5$ 64,006.3
LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
 CEO
 WEBSITElilly.com
 INDUSTRYPharmaceuticals
 EMPLOYEES39000

Eli Lilly & Co Frequently Asked Questions


What is the ticker symbol for Eli Lilly & Co? What does LLY stand for in stocks?

LLY is the stock ticker symbol of Eli Lilly & Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eli Lilly & Co (LLY)?

As of Thu Jul 18 2024, market cap of Eli Lilly & Co is 806.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers. The fair value of Eli Lilly & Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eli Lilly & Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LLY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eli Lilly & Co a good stock to buy?

The fair value guage provides a quick view whether LLY is over valued or under valued. Whether Eli Lilly & Co is cheap or expensive depends on the assumptions which impact Eli Lilly & Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LLY.

What is Eli Lilly & Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, LLY's PE ratio (Price to Earnings) is 131.46 and Price to Sales (PS) ratio is 22.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LLY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eli Lilly & Co's stock?

In the past 10 years, Eli Lilly & Co has provided 0.32 (multiply by 100 for percentage) rate of return.